STRO

Sutro Biopharma, Inc. (STRO) - 10-K Summary

Business Context and Reporting Period

Company: Sutro Biopharma, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Sutro is an oncology company developing site-specific antibody drug conjugates (ADCs) using its proprietary cell-free protein synthesis platform, XpressCF, and site-specific conjugation platform, XpressCF+. The company has no approved products and generates revenue primarily through collaboration agreements and licensing.
Key Assets: The lead wholly-owned preclinical candidate is STRO-004 (anti-Tissue Factor ADC), with an anticipated IND submission in H2 2025. In March 2024, the company licensed STRO-003 to Ipsen. In March 2025, the company announced a strategic review resulting in the deprioritization of its former lead asset, luvelta (STRO-002).

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: The 2024 net loss includes a non-operating realized gain of $32.1 million from the sale of Vaxcyte common stock and a non-cash interest expense of $31.1 million related to the sale of future royalties to Blackstone.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 60% to $62.0 million. This was primarily driven by a $98.7 million decrease in Vaxcyte revenue (due to the recognition of $97.5 million in upfront/option exercise revenue in 2023) and the cessation of revenue from BMS and Merck collaborations following their decisions to terminate clinical development of licensed candidates.
• Expense Increase: R&D expenses increased 40% to $252.0 million, driven by higher external CMO-related activities ($43.0 million increase) and increased preclinical/clinical development costs. G&A expenses decreased 23% to $48.5 million due to cost reduction initiatives.
• Collaboration Activity:
  • Ipsen: Entered an exclusive license agreement for STRO-003 in March 2024, receiving a $50.0 million upfront payment and $25.0 million in stock investment.
  • Astellas: Notified in June 2024 that it would not nominate a third target program, resulting in a contract modification and a $17.8 million cumulative catch-up revenue adjustment.
  • Vaxcyte: Sold remaining equity holdings in 2024 for net proceeds of $74.0 million.
• Manufacturing Strategy: The company plans to wind down its internal manufacturing facility in San Carlos by the end of 2025, transitioning to an outsourced model using Contract Manufacturing Organizations (CMOs).

Guidance, Outlook, and Risks

• Strategic Pivot: In March 2025, management announced a restructuring plan involving a workforce reduction of approximately 50% and the deprioritization of luvelta (STRO-002) to extend the cash runway. The focus is now on three wholly-owned preclinical programs, led by STRO-004.
• Liquidity: As of December 31, 2024, the company held $316.9 million in cash and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months. However, the company expects to incur significant losses in the foreseeable future and will require additional capital to advance clinical development.
• Key Risks:
  • Development Risk: All product candidates are in preclinical stages; there is no guarantee of regulatory approval or commercial success.
  • Collaboration Dependency: Revenue relies heavily on partners (Astellas, Ipsen, Vaxcyte). Partners may terminate agreements or fail to achieve milestones.
  • Manufacturing Transition: Risks associated with transferring manufacturing technology to third-party CMOs and closing the internal facility.
  • Regulatory Uncertainty: No product manufactured on a cell-free platform has received FDA approval, creating uncertainty regarding regulatory requirements.

Investor Verification Checklist

• Cash Runway: Verify the impact of the March 2025 workforce reduction (approx. 50%) on the projected 12-month liquidity runway.
• STRO-004 Timeline: Confirm the anticipated H2 2025 IND submission date for the lead asset STRO-004 and any preclinical data updates.
• Deferred Royalty Obligation: Review the assumptions used to calculate the $180.8 million liability related to the Blackstone royalty sale, as changes in Vaxcyte's sales forecasts will impact non-cash interest expense.
• Manufacturing Transition: Assess the status of technology transfers to CMOs and the timeline for closing the San Carlos facility to ensure no disruption to clinical supply.
• Collaboration Milestones: Monitor the status of the Astellas collaboration (two remaining targets) and the Ipsen STRO-003 program for potential future revenue recognition.